A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.
Veracyte's Chief Accounting Officer, Jonathan Wygant, sold 24,000 shares for $1.1 million after exercising options, reducing his direct ownership by 34.57%. This transaction, along with a subsequent smaller sale, capitalized on the company's rising stock price driven by strong Q1 earnings and raised full-year guidance. The article details the transaction, Wygant's reduced ownership, and Veracyte's financial performance.
Veracyte Stock Surges 117% in a Year: What's Driving the Rally?
Veracyte's stock has surged 117% over the past year, significantly outperforming its industry and the S&P 500, driven by its long-term growth strategy focusing on minimal residual disease testing, international expansion, and new product development. Key catalysts include strong Afirma volumes and a robust financial position with $439 million in cash and no debt. However, macroeconomic factors and competitive intensity in the genomic diagnostics market could pose challenges to its continued growth.
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 3000 Value Benchmark
Veracyte, Inc. (NasdaqGM: VCYT), a global diagnostics company, has been added to the Russell 3000 Value Benchmark. This news follows several other recent additions to various Russell indices, including the Russell 2000 Value, Russell 2000 Value-Defensive, and Russell 3000E Value Benchmarks. The company specializes in tests for thyroid, prostate, breast, interstitial lung diseases, and bladder cancer, with additional tests in development.
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2500 Value Benchmark
Veracyte, Inc. (VCYT) has been added to the Russell 2500 Value Benchmark, as well as several other Russell indices including the Russell 2000 Value Benchmark, Russell 2000 Value-Defensive Index, and Russell 3000 Value Benchmark. This inclusion signifies the company's recognition within key market indices. Veracyte is a global diagnostics company specializing in tests for various cancers and interstitial lung diseases.
VCYT Maintained by Guggenheim -- Price Target Raised to $65
Guggenheim maintained a "Buy" rating for Veracyte (VCYT) and significantly increased its price target from $45.00 to $65.00, reflecting confidence in the company's future growth. Despite this positive analyst outlook and a strong GF Score™ of 75/100, GuruFocus indicates VCYT is 55.1% overvalued at its current price of $59.11 compared to its GF Value™ of $38.11, and insiders have sold $10.1 million in shares recently.
Veracyte (VCYT) Enters Multiple Russell Indexes Is Its Small-Cap Profile Quietly Changing?
Veracyte (VCYT) has been added to several Russell indexes, including the Russell 2000 Defensive and Growth-Defensive, which could significantly increase its institutional investor base and trading liquidity. While this inclusion may boost awareness for the company's cancer diagnostics platform, the core risks and catalysts around new test launches and reimbursement pressures remain unchanged. The article emphasizes that despite potential increased investor attention, fundamental factors like successful execution of new launches and payer support are still critical for Veracyte's long-term success.
Price to book forward of Veracyte, Inc. – NASDAQ:VCYT
This page from TradingView displays financial data for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its Price to Book Forward metric. The content lists various financial tools and market data services provided by TradingView and its partners.
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2000 Value-Defensive Index
Veracyte, Inc. (NasdaqGM: VCYT), a global diagnostics company, has been added to the Russell 2000 Value-Defensive Index. The company provides various diagnostic tests for cancers previously mentioned in the article, such as thyroid cancer and breast cancer, and is developing tests for kidney cancer and lymphoma. Recent news includes an insider selling shares, an analyst raising the price target, and the commercial launch of their Prosigna Breast Test in the U.S.
Enterprise value to revenue forward of Veracyte, Inc. – FWB:12V
This article provides financial information for Veracyte, Inc. (FWB:12V) on TradingView, specifically focusing on its enterprise value to revenue forward. It indicates the market status as closed with no trades, and the content primarily consists of navigation and boilerplate information from the TradingView platform.
Price to sales forward of Veracyte, Inc. – FWB:12V
This article provides financial information for Veracyte, Inc. (FWB:12V), specifically focusing on its price-to-sales forward metric. The data is sourced from exchanges and financial data providers, indicating that the market for this stock was closed with no trades recorded at the time of publication.
Price to sales forward of Veracyte, Inc. – NASDAQ:VCYT
This page provides financial information for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its forward price-to-sales ratio. The content appears to be a financial data page from TradingView, offering an overview of the company's financials for investors and analysts. It details the company's trading on the Nasdaq Stock Market and includes various tools and resources available on the TradingView platform.
Enterprise value to EBIT forward of Veracyte, Inc. – NASDAQ:VCYT
This article provides financial information for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its enterprise value to EBIT forward. The content is presented within the TradingView platform, which offers various financial tools and data.
Price to earnings forward of Veracyte, Inc. – FWB:12V
This article provides financial information for Veracyte, Inc. (FWB:12V), focusing on its forward price-to-earnings ratio. It states that the market is currently closed with no trades recorded and offers data made by humans from various financial services.
Enterprise value to EBITDA forward of Veracyte, Inc. – NASDAQ:VCYT
This article provides a brief snapshot of the "Enterprise value to EBITDA forward" for Veracyte, Inc. (NASDAQ: VCYT) according to TradingView. It indicates that the market was closed at the time the data was viewed, with no trades recorded. The content is primarily a data point with no further analysis or discussion.
Veracyte, Inc. Actuals & Estimates (NASDAQ:VCYT)
This article provides an overview of Veracyte, Inc. (NASDAQ: VCYT) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, such as recent earnings, revenue, net income, and market capitalization. The article notes that Veracyte does not pay dividends and has 755 employees as of June 28, 2026.
Veracyte, Inc. Actuals & Estimates (MUN:12V)
This article provides an overview of Veracyte, Inc. (MUN:12V) financials, analyst estimates, and key company data. It includes details on past earnings performance, revenue, EBITDA, and analyst price targets, alongside upcoming earnings report dates. The article also addresses frequently asked questions about the company's stock ticker, historical prices, and dividend policy.
Veracyte, Inc. Actuals & Estimates (DUS:12V)
This article provides an overview of Veracyte, Inc. (12V) stock details, including financial actuals, analyst estimates, and key performance indicators. It covers income statements, balance sheets, cash flow, and valuation metrics, along with answers to frequently asked questions about its stock forecast, historical prices, earnings, revenue, net income, dividends, and employee count. The company last reported earnings of 0.45 EUR per share, surpassing estimates, and its next earnings report is expected on August 11, 2026.
Veracyte Inc (VCYT) Shares Surge 3.1% -- What GF Score of 75 Tell Investors
Veracyte Inc (VCYT) shares surged 3.1% to $58.59 on June 25, 2026, marking a 30.0% appreciation over the last month. Despite a strong GF Score of 75/100, indicating above-average performance, the stock is considered "Significantly Overvalued" with a current price considerably above its GF Value of $38.10. Insider selling totaling $10.1 million over the past three months, with no buying activity, suggests caution for potential investors due to concerns about the stock's valuation and future performance.
VCYT Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Veracyte, Inc. (VCYT) stock, based on analyst ratings and current market performance. It details the company's financial metrics, including recent earnings and revenue, and answers frequently asked questions about its stock performance, market capitalization, and future outlook. The information presented is not investment advice.
Veracyte Inc (VCYT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Veracyte Inc (VCYT), detailing its current price momentum, support and resistance levels, and signals from various technical indicators like MACD, RSI, and moving averages. As of June 25, 2026, VCYT has a price momentum score of 9.58, and indicators suggest a "Buy" signal based on both technical indicators and moving averages. The stock is currently trading between a resistance level of $64.44 and a support level of $48.51.
Veracyte Jumps 7.2% Amid Sector-Wide Rally
Veracyte (VCYT) shares surged 7.2% on Wednesday, closing at $57.67, as diagnostic and research stocks experienced a broad sector-wide rally. This coordinated upward movement, which also saw gains for peers like CELC, ACAD, and RLAY, suggests investor confidence in the sector rather than company-specific news. Trading volume for VCYT was significantly higher at 241,949, bringing its market capitalization to $4.6 billion.
Veracyte stock hits 52-week high at 55.32 USD
Veracyte Inc (VCYT) stock reached a new 52-week high of $55.32, reflecting a 103.36% increase over the past year. Despite its current trading price being slightly below this peak and InvestingPro suggesting it might be overvalued, the company shows strong fundamentals with a $4.29 billion market cap and a 0.3 PEG ratio. Analyst earnings revisions are positive, and the company recently launched new diagnostic tests and secured Medicare coverage for another, contributing to its strong market position and future growth potential.
Veracyte (VCYT) director logs 3,729-share Rule 10b5-1 stock sale
Veracyte's director, Karin Eastham, sold 3,729 shares of common stock on June 18, 2026, through open-market transactions. These sales were executed under a pre-arranged Rule 10b5-1 trading plan established on September 5, 2025, with shares sold at weighted average prices of $52.78 and $53.55. Following these transactions, Eastham holds 15,626 shares of common stock directly.
Form 4 Veracyte Inc For: 22 June By Investing.com
This article from Investing.com is a Form 4 filing for Veracyte Inc., published on June 22. It indicates an insider transaction for the company VCYT. The filing includes the date of the transaction.
VCYT|Veracyte Inc|Price:53.630|Chg%:2.34
Veracyte Inc (VCYT) shows strong fundamentals and high growth potential, with its revenue growing 43.23% annually over the last three years. The stock is considered fairly valued and has seen significant institutional ownership, though there was a slight decrease in the last quarter. Analysts recommend a "Buy" with a target price of $49.36, and the stock has performed well over the past year, increasing by over 100%.
VERACYTE, INC. SEC Filing Form 144
This SEC filing is a Form 144 notice filed by VERACYTE, INC. (VCYT) on June 18, 2026, detailing a proposed sale of securities. The form outlines information about the filer, issuer, and the class of common securities to be sold through Morgan Stanley Smith Barney LLC. It also specifies the acquisition details and confirms no adverse material information is withheld.
Veracyte Inc (VCYT) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Veracyte Inc (VCYT), noting its current valuation score of 7.13, which ranks 260 out of 389 in its industry. The P/E ratio is currently 48.10, significantly below its recent high but well above its recent low. The article also indicates that relevant P/B, P/S, and P/CF data have not yet been disclosed by the company.
Veracyte Inc (VCYT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Veracyte Inc (VCYT) has an earnings forecast score of 8.50, ranking 106 out of 389 in its industry. The average price target is $48.00, with analysts largely issuing a "Buy" rating. The company's expected revenue for the next quarter is $144.54 million, and its previous quarter's EPS of $0.52 exceeded the market expectation of $0.36.
Veracyte Inc (VCYT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Veracyte Inc (VCYT), detailing its regional revenue contribution. As of the last update on April 6, the company generated $496.60 million (96.03%) from the United States and $20.55 million (3.97%) internationally. The article notes that relevant data for business segments for recent fiscal years (FY2021-FY2025) have not yet been disclosed by the company.
Veracyte Inc (VCYT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical data on dividends and stock splits for Veracyte Inc (VCYT). It states that Veracyte has not distributed any dividends over the past five years and has no record of stock splits. The company's current stock price, market capitalization, and P/E ratio are also displayed.
Veracyte Inc (VCYT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Veracyte Inc (VCYT), outlining its major shareholders and institutional holdings. It provides a breakdown of principal shareholders like BlackRock and Artisan Partners, along with their respective proportions. The report also includes historical institutional shareholding data and lists related ETFs with their proportions in VCYT.
Veracyte Inc (VCYT) Financial Health: Profitability & Balance Sheet Analysis
Veracyte Inc (VCYT) has a strong financial health score of 9.24, ranking 6th in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 21.49% to $139.07 million and a net profit increase of 307.36%. Its financial robustness and high operating efficiency indicate a healthy financial position for the company.
Veracyte stock hits 52-week high at 50.81 USD By Investing.com
Veracyte Inc's stock reached a new 52-week high of $50.71, currently trading near its peak despite InvestingPro analysis suggesting it might be overvalued. The company has seen an 84.5% increase in its stock value over the past year, supported by a strong financial health score and recent positive developments including new product launches and favorable analyst ratings. These developments underscore Veracyte's expansion in diagnostic capabilities and market reach.
Veracyte (VCYT) director Jens Holstein awarded 5,272 restricted stock units
Veracyte (VCYT) director Jens Holstein was awarded 5,272 restricted stock units (RSUs) on June 11, 2026, as reported in a Form 4 SEC filing. These RSUs vest in full on the first anniversary of the grant date or earlier if there's a change in control or immediately before the next annual stockholder meeting. Following this grant, Holstein directly holds 32,471 shares of Veracyte common stock.
Veracyte stock hits 52-week high at 50.81 USD
Veracyte Inc.'s stock recently hit a 52-week high of $50.71, marking an 84.5% increase over the past year. Despite this, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value, although its PEG ratio of 0.27 indicates reasonable valuation based on earnings growth expectations. The company also announced positive results from its OPTIMA trial, new analyst ratings, and the launch of new diagnostic tests, including the Prosigna Breast Risk of Recurrence test and the TrueMRD Monitoring Test.
Veracyte (VCYT) director Eliav Barr receives 5,272 restricted stock units
Veracyte (VCYT) director Eliav Barr was granted 5,272 restricted stock units (RSUs) on June 11, 2026, increasing his direct holdings to 56,461 shares. These RSUs vest fully on the first anniversary of the grant date or immediately before the company's next annual meeting, whichever comes first, or upon a change in company control. The grant price per share was $0.00, indicating it is a compensation-related award rather than a market purchase.
Director at Veracyte (VCYT) receives grant of 5,272 restricted stock units
Veracyte (VCYT) director Karin Eastham was granted 5,272 restricted stock units (RSUs) on June 11, 2026, at no cash cost, increasing her direct holdings to 18,826 shares. These RSUs vest fully on the first anniversary of the grant date, or immediately before the company's next annual stockholder meeting, or upon a change in control. This transaction was reported in a Form 4 filing, indicating it as an acquisition of non-derivative common stock as compensation.
Veracyte (VCYT) director Robert Epstein receives 5,272-share RSU grant
Veracyte (VCYT) director Robert S. Epstein was granted 5,272 restricted stock units (RSUs) on June 11, 2026, as equity compensation. These RSUs were priced at $0.00 per share and vest fully on the first anniversary of the grant date or earlier under specific conditions, such as the next annual stockholders' meeting or a change in control. Following this transaction, Epstein directly holds 57,718 shares of Veracyte common stock.
[Form 4] VERACYTE, INC. Insider Trading Activity
VERACYTE, INC. director Muna Bhanji reported an acquisition of 5,272 shares of common stock through a restricted stock unit award on June 11, 2026, as detailed in a recent Form 4 filing. These units were granted at no cash cost and will vest in full either on the first anniversary of the grant date or immediately before the company’s next annual stockholder meeting, or upon a change in control of the company. Following this transaction, Muna Bhanji directly holds 44,582 shares in Veracyte.
Evan Jones of Veracyte (NASDAQ: VCYT) receives 5,272 restricted stock units
Veracyte director Evan Jones received an equity award of 5,272 restricted stock units on June 11, 2026, increasing his direct holdings to 34,634 shares. These units were granted at no purchase price and will fully vest on the first anniversary of the grant date, or earlier under certain conditions like a change in company control. This transaction was reported via a Form 4 filing with the SEC, indicating compensation rather than a market purchase.
Director at VERACYTE, INC. (VCYT) awarded 5,272 restricted stock units
VERACYTE, INC. director David Brent Shafer was awarded 5,272 restricted stock units (RSUs) on June 11, 2026, as equity compensation. These RSUs will fully vest on the first anniversary of the grant date or earlier under certain conditions, such as immediately before the next annual stockholder meeting or upon a change in control. Following this award, Shafer directly holds 31,100 shares of Veracyte common stock.
Assessing Veracyte (VCYT) Valuation After New Prosigna Launch And Decipher Prostate Clinical Milestones
Veracyte (VCYT) is gaining momentum following the U.S. launch of its Prosigna Breast Risk of Recurrence test and new Phase III data for breast and prostate cancer. Despite recent gains, the company's valuation is a point of discussion, with analysts pegging its fair value at $49.10, indicating it's slightly undervalued, while a high P/E ratio suggests potential valuation risk. Investors are encouraged to review the company's fundamentals and growth expectations in light of these mixed signals.
Veracyte, Inc. 2023 Equity Incentive Plan Amended – SEC 8-K Filing Details and Company Information
Veracyte, Inc. held its Annual Meeting of Shareholders, approving key governance items including director elections, auditor ratification, and executive compensation. A significant outcome was the approval of an amendment to the 2023 Equity Incentive Plan, which aims to attract and retain talent by offering various equity awards. This amendment has implications for share dilution, employee motivation, and overall shareholder value, with up to 15,000,000 shares reservable for Incentive Stock Options.
Veracyte (VCYT) investors back 3.5M-share equity plan increase and elect full board
Veracyte, Inc. shareholders approved an amendment to the company's 2023 Equity Incentive Plan, increasing the number of shares reserved for issuance by 3,500,000. Additionally, all nine nominated directors were elected to serve until the 2027 annual meeting, and Ernst & Young LLP was ratified as the independent registered public accounting firm for 2026. Shareholders also approved the compensation of named executive officers on a non-binding advisory basis.
Veracyte, Inc. $VCYT Shares Sold by GW&K Investment Management LLC
GW&K Investment Management LLC reduced its stake in Veracyte, Inc. by 11.2% in the fourth quarter, selling 143,396 shares. This divestment occurred as Veracyte's shares recently surged by 4.2% to $49.24 after the company reported stronger-than-expected Q1 earnings and revenue. Despite insider selling by the CEO and an EVP, analysts maintain a "Moderate Buy" rating for VCYT with an average target price of $47.57.
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
This article analyzes the hypothetical return of a $1000 investment in Veracyte (VCYT) made ten years ago, calculating its current value and percentage gain. It delves into Veracyte's business model, including its genomic tests for cancer diagnosis, revenue streams, and recent performance. The piece also discusses analyst forecasts for VCYT, highlighting growth drivers, future launches, and potential risks, while comparing its performance to the S&P 500 and gold.
Here's why Veracyte (VCYT) is a strong growth stock
This article from MSN focuses on why Veracyte (VCYT) is considered a strong growth stock. It likely discusses factors contributing to its growth potential, such as market position, financial performance, or innovative products/services.
Veracyte Inc (VCYT) Stock Down 3.0% but Still Overvalued -- GF S
Veracyte Inc (VCYT) shares dropped 3.0% to $47.29 on June 8, 2026, yet GuruFocus assesses the stock as 24.6% overvalued with a GF Value™ estimate of $37.94. Despite a strong GF Score™ of 78/100, driven by financial strength and growth, its profitability ranks lower. Adding to concerns, insiders have sold $9.9 million worth of stock in the last three months with no reported buying, suggesting potential apprehension about the current valuation.
Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from Brokerages
Veracyte, Inc. (NASDAQ:VCYT) has an average "Moderate Buy" rating from nine brokerages, with an average 12-month price target of $47.57. This comes after the biotechnology company reported better-than-expected Q1 earnings with a 21.5% year-over-year revenue increase. Despite strong earnings and positive news on clinical trials, there have been mixed analyst updates and significant insider stock sales by the CEO and another executive.
Veracyte (VCYT) Is Up 9.4% After New Phase III Data Validates Prosigna Chemotherapy-Guidance Role – Has The Bull Case Changed?
Veracyte (VCYT) has seen a 9.4% stock increase following strong Phase III clinical data for its Prosigna Breast and Decipher Prostate genomic tests, and the upcoming U.S. launch of Prosigna. The new data supports the use of these tests in guiding chemotherapy decisions, potentially sparing patients from unnecessary treatment. This strengthened clinical validation is expected to impact Veracyte's investment narrative, with potential for increased ordering volumes and reimbursement traction, though execution risks and valuation remain key considerations.
